These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18978068)

  • 1. Immunosuppressive therapy and post-transplant malignancy.
    Domhan S; Zeier M; Abdollahi A
    Nephrol Dial Transplant; 2009 Apr; 24(4):1097-103. PubMed ID: 18978068
    [No Abstract]   [Full Text] [Related]  

  • 2. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 3. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 4. [Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants].
    Nishikido M; Kanekake H; Harada T
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():634-8. PubMed ID: 16523968
    [No Abstract]   [Full Text] [Related]  

  • 5. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 7. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
    Conzett KB; Kolm I; Jelcic I; Kamarachev J; Dummer R; Braun R; French LE; Linnebank M; Hofbauer GF
    Arch Dermatol; 2011 Aug; 147(8):991-2. PubMed ID: 21844470
    [No Abstract]   [Full Text] [Related]  

  • 8. Fingolimod: cardiovascular deaths.
    Prescrire Int; 2012 Apr; 21(126):99. PubMed ID: 22515137
    [No Abstract]   [Full Text] [Related]  

  • 9. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation.
    Brinkmann V; Pinschewer D; Chiba K; Feng L
    Trends Pharmacol Sci; 2000 Feb; 21(2):49-52. PubMed ID: 10664606
    [No Abstract]   [Full Text] [Related]  

  • 10. Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues.
    Högenauer K; Billich A; Pally C; Streiff M; Wagner T; Welzenbach K; Nussbaumer P
    ChemMedChem; 2008 Jul; 3(7):1027-9. PubMed ID: 18383466
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
    Leypoldt F; Münchau A; Moeller F; Bester M; Gerloff C; Heesen C
    Neurology; 2009 Mar; 72(11):1022-4. PubMed ID: 19289744
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 13. Fingolimod exacerbated affective psychosis?
    Fitzpatrick A; Clark SR; Newcombe R; Davis A; Baune BT
    Aust N Z J Psychiatry; 2013 Apr; 47(4):399-400. PubMed ID: 23042940
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM
    N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunology: Surprising side effects.
    Bevan MJ; Fink PJ
    Nature; 2008 Aug; 454(7206):837-8. PubMed ID: 18704076
    [No Abstract]   [Full Text] [Related]  

  • 16. Fingolimod. Check cardiovascular status again on treatment resumption.
    Prescrire Int; 2014 Jan; 23(145):13. PubMed ID: 24516904
    [No Abstract]   [Full Text] [Related]  

  • 17. [The risk of malignancy after organ transplantation].
    Gürlich R; Novotný J; Stríz I; Honsová E; Oliverius M; Janousek L; Pokorná E; Maruna P
    Cas Lek Cesk; 2005; 144(9):597-600; discussion 600-1. PubMed ID: 16193937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
    Gutierrez-Dalmau A; Campistol JM
    Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis.
    Gallego-Pinazo R; España-Gregori E; Casanova B; Pardo-López D; Díaz-Llopis M
    J Neuroophthalmol; 2011 Sep; 31(3):292-3. PubMed ID: 21826025
    [No Abstract]   [Full Text] [Related]  

  • 20. Sudden unexpected death on fingolimod.
    Lindsey JW; Haden-Pinneri K; Memon NB; Buja LM
    Mult Scler; 2012 Oct; 18(10):1507-8. PubMed ID: 22300970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.